Cantor Fitzgerald Starts Corbus Pharmaceuticals (CRBP) at Buy

October 4, 2016 4:11 PM EDT
Get Alerts CRBP Hot Sheet
Price: $8.95 +22.60%

Rating Summary:
    0 Buy, 0 Hold, 0 Sell

Rating Trend: = Flat

Today's Overall Ratings:
    Up: 14 | Down: 11 | New: 8
Trade CRBP Now!
Join SI Premium – FREE

Get instant alerts when news breaks on your stocks. Claim your 2-week free trial to StreetInsider Premium here.

Cantor Fitzgerald initiates coverage on Corbus Pharmaceuticals (NASDAQ: CRBP) with a Buy rating and a price target of $17.00.

Analyst Elemer Piros commented, "We are initiating coverage of Corbus Pharmaceutical Holdings with a BUY rating and 12-month price target of $17/share. We anticipate Corbus to achieve three clinical inflection points during the next 12 months, beginning with the first in November around the American College of Rheumatology (ACR) meeting."

For an analyst ratings summary and ratings history on Corbus Pharmaceuticals click here. For more ratings news on Corbus Pharmaceuticals click here.

Shares of Corbus Pharmaceuticals closed at $6.87 yesterday.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments, Hot New Coverage, New Coverage

Related Entities

Cantor Fitzgerald

Add Your Comment